Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Purchases $79,600.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) Director John B. Bode bought 10,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. The trade was a 33.33 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock traded down $0.06 during mid-day trading on Tuesday, reaching $8.15. The company's stock had a trading volume of 235,370 shares, compared to its average volume of 584,064. The firm's fifty day moving average price is $7.90 and its two-hundred day moving average price is $8.19. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a market capitalization of $441.05 million, a P/E ratio of -4.14 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP grew its position in shares of Zevra Therapeutics by 2.2% during the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company's stock valued at $34,524,000 after purchasing an additional 90,940 shares in the last quarter. Velan Capital Investment Management LP boosted its stake in Zevra Therapeutics by 50.0% during the fourth quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company's stock valued at $2,502,000 after buying an additional 100,000 shares during the period. Squarepoint Ops LLC grew its position in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after buying an additional 4,384 shares in the last quarter. ProShare Advisors LLC purchased a new position in Zevra Therapeutics during the fourth quarter worth about $145,000. Finally, Millennium Management LLC increased its stake in Zevra Therapeutics by 138.2% in the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company's stock worth $1,944,000 after acquiring an additional 135,246 shares during the last quarter. Institutional investors own 35.03% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZVRA. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Guggenheim raised their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $22.29.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.